NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
20.58
+0.57 (2.85%)
Nov 21, 2024, 12:04 PM EST - Market open

NAMS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
33.5914.09102.69--
Revenue Growth (YoY)
78.77%-86.28%---
Gross Profit
33.5914.09102.69--
Selling, General & Admin
59.9337.6319.5161.38
Research & Development
157.8159.4286.7428.974.05
Operating Expenses
217.73197.06106.2534.985.43
Operating Income
-184.13-182.97-3.56-34.98-5.43
Interest Expense
---0.29-0.41-0.34
Interest & Investment Income
15.0611.28---
Currency Exchange Gain (Loss)
6.495.06-9.751.710.02
Other Non Operating Income (Expenses)
---8-7.22-
EBT Excluding Unusual Items
-162.58-166.63-21.59-40.9-5.75
Other Unusual Items
-36.31-10.28-1.04-0.88-
Pretax Income
-198.89-176.91-22.63-41.79-5.75
Income Tax Expense
0.030.03---
Net Income
-198.92-176.94-22.63-41.79-5.75
Net Income to Common
-198.92-176.94-22.63-41.79-5.75
Shares Outstanding (Basic)
908219115
Shares Outstanding (Diluted)
908219115
Shares Change (YoY)
45.44%333.20%72.75%119.58%-
EPS (Basic)
-2.21-2.15-1.19-3.81-1.15
EPS (Diluted)
-2.21-2.15-1.19-3.81-1.15
Free Cash Flow
-154.83-141.2410.44-29.54-5.98
Free Cash Flow Per Share
-1.72-1.720.55-2.69-1.20
Gross Margin
100.00%100.00%100.00%--
Operating Margin
-548.12%-1298.56%-3.46%--
Profit Margin
-592.12%-1255.76%-22.04%--
Free Cash Flow Margin
-460.88%-1002.43%10.17%--
EBITDA
-184.06-182.92-3.55-34.97-5.43
EBITDA Margin
---3.45%--
D&A For EBITDA
0.080.050.010.010
EBIT
-184.13-182.97-3.56-34.98-5.43
EBIT Margin
---3.46%--
Source: S&P Capital IQ. Standard template. Financial Sources.